Ticker
ALEC

Price
7.49
Stock movement down
-0.26 (-3.35%)
Company name
Alector Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
616.63M
Ent value
848.93M
Price/Sales
2.71
Price/Book
2.30
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-62.40%
3 year return
-25.56%
5 year return
-
10 year return
-
Last updated: 2022-11-29

DIVIDENDS

ALEC does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF1.27
Price to FCF1.28
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales2.71
Price to Book2.30
EV to Sales3.73

FINANCIALS

Per share

Loading...
Per share data
Current share count82.33M
EPS (TTM)-0.35
FCF per share (TTM)5.90

Income statement

Loading...
Income statement data
Revenue (TTM)227.45M
Gross profit (TTM)227.45M
Operating income (TTM)-28.85M
Net income (TTM)-28.77M
EPS (TTM)-0.35
EPS (1y forward)-1.55

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)-12.68%
Profit margin (TTM)-12.65%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash454.62M
Net receivables12.82M
Total current assets890.93M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets954.46M
Accounts payable6.75M
Short/Current long term debt46.61M
Total current liabilities142.88M
Total liabilities686.92M
Shareholder's equity267.54M
Net tangible assets267.54M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)486.33M
Capital expenditures (TTM)2.99M
Free cash flow (TTM)483.34M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-10.76%
Return on Assets-3.01%
Return on Invested Capital-10.76%
Cash Return on Invested Capital180.66%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open7.67
Daily high7.78
Daily low7.37
Daily Volume380K
All-time high39.49
1y analyst estimate24.44
Beta1.13
EPS (TTM)-0.35
Dividend per share-
Ex-div date-
Next earnings date22 Feb 2023

Downside potential

Loading...
Downside potential data
ALECS&P500
Current price drop from All-time high-81.03%-17.12%
Highest price drop-82.58%-56.47%
Date of highest drop9 Nov 20229 Mar 2009
Avg drop from high-44.85%-11.46%
Avg time to new high44 days13 days
Max time to new high354 days1805 days
COMPANY DETAILS
ALEC (Alector Inc) company logo
Marketcap
616.63M
Marketcap category
Small-cap
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Employees
237
Investor relations
-
SEC filings
CEO
Arnon Rosenthal
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated t...
November 29, 2022
Alector ( NASDAQ:ALEC ) Third Quarter 2022 Results Key Financial Results Revenue: US$14.9m (down 92% from 3Q 2021). Net...
November 10, 2022
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 9, 2022
Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiated first-in-human Phase 1 trial of AL044, the company’s third n...
November 8, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announ...
November 7, 2022
Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Alector, Inc...
November 4, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announ...
November 3, 2022
Promotion demonstrates Alector’s commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned the Great ...
October 13, 2022
AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies thr...
September 12, 2022
The consensus price target hints at a 58.2% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...
August 9, 2022
Next page